Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Necitumumab + Gemcitabine in EGFR-Amplified Advanced Biliary Tract Cancer
jRCTs031230259Phase 2Recruiting
- Sponsor
- Yokohama City University
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab and gemcitabine in biliary cancer, sponsored by Yokohama City University. Primary endpoint: objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
necitumumabgemcitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCTs031230259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230259.